RxDoctor Payments DataLook up a doctor →

Aashoo Mentreddi, MD

Neurology · York, MENPI 1215226725

Payments from drug & device makers

$277,115in general payments, 2019–2025

Across 792 payments — averaging $349.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$117K
  • Acorda Therapeutics, Inc$89K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41K
  • UCB SA$12K
  • Merz Pharmaceuticals, LLC$6K
  • Sunovion Pharmaceuticals Inc.$4K
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$6,2154%
  • Speaking & faculty fees$145,97483%
  • Travel & lodging$10,3826%
  • Food & beverage$13,2158%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)242$116,640
Acorda Therapeutics, Inc119$89,453
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)17$40,667
UCB SA1$12,300
Merz Pharmaceuticals, LLC16$5,742
Sunovion Pharmaceuticals Inc.24$3,592
Acadia Pharmaceuticals Inc58$1,818
Boston Scientific36$718
UCB, Inc.28$600
Abbott9$477
Medtronic(2 entities)7$367
Novartis16$276
Pfizer16$264
Eisai Inc.9$246
Neurocrine Biosciences, Inc.12$245
Argenx US, Inc.7$235
Lilly USA, LLC11$230
Amneal Pharmaceuticals LLC12$219
AstraZeneca(2 entities)10$212
Lundbeck LLC11$203
Ipsen Biopharmaceuticals, Inc8$190
Teva Pharmaceuticals USA, Inc.8$187
Adamas Pharmaceuticals, Inc.8$162
Grifols USA, LLC7$158
SK Life Science, Inc.7$146
MDD US Operations, LLC11$137
Bristol Myers Squibb7$125
TG Therapeutics, Inc.6$123
Biogen6$121
Genentech USA, Inc.5$113
Neurelis, Inc.5$101
Amgen4$90
Akcea Therapeutics, Inc.2$88
Greenwich Biosciences, Inc.3$85
Corium, LLC4$74
Octapharma USA, Inc.3$63
Avion Pharmaceuticals4$62
Sumitomo Pharma America, Inc.3$62
Upsher-smith Laboratories LLC3$49
Alnylam Pharmaceuticals Inc.2$47
Sanofi2$41
Biohaven Pharmaceutical Holding Company Ltd.2$34
Otsuka America Pharmaceutical, Inc.2$33
Supernus Pharmaceuticals, Inc.2$32
Kyowa Kirin, Inc.1$27
Biohaven Pharmaceuticals, Inc.2$24
Takeda Pharmaceuticals U.S.A., Inc.1$24
Revance Therapeutics, Inc.1$24
Azurity Pharmaceuticals, Inc.1$20
Life Molecular Imaging Ltd1$20
Aquestive Therapeutics, Inc.1$19
Hospira, Inc.1$19
Tanabe Pharma America, Inc.1$19
Johnson & Johnson1$15
Cala Health, Inc.1$15
NS Pharma, Inc.1$13
Jazz Pharmaceuticals Inc.1$13
Avanir Pharmaceuticals, Inc.1$13
Xeris Pharmaceuticals, Inc.1$12
Arbor Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,115 in reported general payments places this provider in the 90th percentile of 69 neurology providers in Maine.

See all neurology providers in Maine

Medicare billing

Part B allowed, 2024
$330,319
Medicare patients
427
Services billed
22,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine34$349,845
RytaryCarbidopa/Levodopa199$293,197
IngrezzaValbenazine Tosylate25$209,777
GocovriAmantadine Hcl24$58,204
Carbidopa-LevodopaCarbidopa/Levodopa629$30,123
QuliptaAtogepant23$28,724
Carbidopa-Levodopa ErCarbidopa/Levodopa297$9,682
Carbidopa14$4,932
Rasagiline Mesylate24$4,919
Entacapone42$3,918
AmantadineAmantadine Hcl44$1,983
Donepezil Hcl177$1,888
Rivastigmine12$1,842
Gabapentin147$1,500
Midodrine Hcl24$1,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$187$349,84534 claims
Amneal Pharmaceuticals LLCRytary$219$293,197199 claims
Neurocrine Biosciences, Inc.Ingrezza$245$209,77725 claims
MDD US Operations, LLCGocovri$137$58,20424 claims
AbbVieQulipta$116,640$28,72423 claims
Upsher-smith Laboratories LLCTopiramate$49$42849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 neurology providers in Maine.

Other neurology in York

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →